Results Room · BSE

Quarterly results: Jul–Sep 2025 (Q2 FY26)

Data as of 26 Oct 2026 · Jul–Sep 2025 results from BSE filings

4,209 companies have reported

26 companies grew fast at a fair price

How this screen works

A strong quarter at a price that still looks fair for the growth. Profit up more than 20% & revenue up more than 15% on the same quarter last year, operating profit (EBITDA) up more than 20% too, operating margin higher than a year ago, EPS up more than 20% (restated for any split or bonus), market cap above ₹2,000 crore, and a PEG below 2 (P/E divided by 12-month EPS growth in %; by the growth of the latest financial year when our results do not reach the four quarters a year earlier). When one-off (exceptional) items come to more than a quarter of 12-month pre-tax profit, P/E & EPS growth leave them out (profit before tax & those items, taxed at 25%). The growth used in PEG is capped at 100%, and PEG is left blank when 12-month EPS a year earlier was below ₹1, because growth from a tiny base makes any P/E look cheap. A PEG near 1 means you pay about one P/E point per point of growth. Profit jumps the business did not earn are left out: when profit more than doubles but operating profit grew far less, or when exceptional items are material and profit before tax without them grew 20% or less. Banks, lenders & insurers are left out because operating profit & margin do not describe their business.

Show asPrefer numbers? Switch to the table to see every figure in one sortable list.

Market cap at leastAny Add your own filtersRevenue, profit, P/E & morePremium filters

Companies on this list26

Revenue up vs last year100%26 of 26

Operating margin up vs last year100%26 of 26

Price, last 12 months 50-day average 200-day average

ASM Technologies Ltd.IT - SoftwareProfit +1324%, revenue +387%, PEG 1.0
Profit YoY
+1323.6%
Revenue YoY
+387.1%
PEG
0.99
Fredun Pharmaceuticals LimitedPharmaceuticals & BiotechnologyProfit +128%, revenue +34%, PEG 0.3Why Apr to Jun profit up 94%; moving into pet care
Profit YoY
+127.7%
Revenue YoY
+34.3%
PEG, full year
0.34
Read the full storyHide the story
Fredun's Apr to Jun sales rose 90.7% to ₹228 crore & profit rose 94% to ₹13.2 crore. On 8 Oct it set out a plan to move from making medicines for other firms to selling only its own brands by 2029, including two pet-care deals.
Apr to Jun profit nearly doubled to ₹13.2 crore on sales up 91%, & it is buying into pet care
What Fredun Pharmaceuticals does
Fredun Pharmaceuticals is a Mumbai drug maker that has mostly made medicines for other companies (OEM, original equipment manufacturing: products that other firms sell under their own names) & exports to 53 countries. It is building its own brands in generic medicines, wellness products & pet care.
What is behind it
The company reported its Apr to Jun 2026 results in early August: income rose 90.4% to ₹228.3 crore & profit rose 94.6% to ₹13.2 crore, according to Sahi. On 8 Oct it filed a business update: it has taken a 26% stake in Goodman Vetcare, a Mumbai pet pharmacy chain, at a valuation of ₹300 crore, & bought the Furlicks pet-wellness brand from USV. It aims for a fully branded portfolio by 2029, to double revenue & profit in 3 to 4 years, & expects a 40,000 sq ft block at its Palghar plant to start in October. The shares rose 13.7% in the week to 9 Oct, MarketsMOJO reported; in the week to 16 Oct it filed only a routine certificate.
How big is it
A 26% stake at a ₹300 crore valuation works out to about ₹78 crore, against ₹227.8 crore of sales in Apr to Jun. Sales over the last four quarters were about ₹742 crore.
Researched 19 Oct
CarTrade Tech LimitedRetailingProfit +109%, revenue +25%, PEG 1.2
Profit YoY
+108.5%
Revenue YoY
+25.4%
PEG
1.21
+23 more companiesSubscribe or sign up free to see 5

Amounts in ₹ crore. A screen of reported numbers, not a list of recommendations.